CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) CFO Kelly Gold acquired 10,000 shares of CAMP4 Therapeutics stock in a transaction on Monday, August 31st. The shares were purchased at an average cost of $3.96 per share, for a total transaction of $39,600.00. Following the acquisition, the chief financial officer owned 10,000 shares in the company, valued at approximately $39,600. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Kelly Gold also recently made the following trade(s):
- On Monday, August 3rd, Kelly Gold bought 6,551 shares of CAMP4 Therapeutics stock. The stock was purchased at an average cost of $1.65 per share, with a total value of $10,809.15.
CAMP4 Therapeutics Stock Down 1.8%
CAMP stock opened at $4.41 on Friday. The company has a market cap of $276.73 million, a P/E ratio of -1.90 and a beta of 0.27. CAMP4 Therapeutics Corporation has a twelve month low of $1.46 and a twelve month high of $7.75. The business has a fifty day moving average of $4.13 and a 200-day moving average of $4.35.
Institutional Trading of CAMP4 Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. Jupiter Topco LLC bought a new position in CAMP4 Therapeutics during the 2nd quarter worth approximately $27,581,000. Janus Henderson Group PLC boosted its position in shares of CAMP4 Therapeutics by 35.9% during the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares in the last quarter. 5AM Venture Management LLC bought a new position in shares of CAMP4 Therapeutics during the second quarter worth $25,647,928. Vivo Capital LLC grew its holdings in shares of CAMP4 Therapeutics by 8.3% in the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock valued at $26,031,000 after buying an additional 325,000 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in shares of CAMP4 Therapeutics in the 4th quarter valued at $14,938,000.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on CAMP. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Weiss Ratings lowered shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. UBS Group set a $15.00 target price on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Finally, Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 10th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.56.
Read Our Latest Report on CAMP
CAMP4 Therapeutics Company Profile
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
See Also
- Five stocks we like better than CAMP4 Therapeutics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
